Direct Contraindications Between Antidepressants and Wegovy
Wegovy (semaglutide) has no absolute contraindications listed specifically for antidepressants in its FDA-approved labeling. No major drug interaction databases, such as those from the FDA or Lexicomp, flag antidepressants as contraindicated with semaglutide.[1][2] Wegovy is contraindicated for conditions like personal/family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or known hypersensitivity to semaglutide.[1]
Common Antidepressants and Potential Interactions
SSRIs (e.g., sertraline, fluoxetine), SNRIs (e.g., duloxetine, venlafaxine), and others like bupropion show no pharmacokinetic interactions with semaglutide—no changes in blood levels or metabolism via CYP enzymes.[2][3]
- SSRIs/SNRIs: Wegovy's GI side effects (nausea, delayed gastric emptying) may alter oral antidepressant absorption slightly, but clinical studies report no significant issues.[3]
- Bupropion: Shares depression treatment but no direct contraindication; monitor for additive effects on appetite suppression.[4]
- MAOIs (e.g., phenelzine): Rare use today; theoretical risk of hypertensive crisis if combined with tyramine-rich foods affected by Wegovy's GI slowdown, but not documented as contraindicated.[2]
Risks and Monitoring Needs
Patients on antidepressants report higher nausea or psychiatric side effects with Wegovy in post-marketing data, possibly due to overlapping profiles rather than direct interactions.[5]
- Depression risk: Wegovy trials excluded severe psychiatric patients, but real-world use shows no increased suicidality signal with antidepressants.[1][6]
- Weight loss effects: Antidepressants like mirtazapine or paroxetine can cause weight gain, potentially countering Wegovy—clinicians adjust doses accordingly.[4]
Monitor for GI intolerance or mood changes; start Wegovy at low doses.
Clinical Evidence from Trials
Wegovy STEP trials included patients with depression (up to 10-15% on antidepressants) without excess adverse events or efficacy loss.[6] No dedicated interaction studies exist, but semaglutide's minimal CYP impact supports safety.[3]
Patient and Provider Advice
Consult a doctor for individual risks, especially with psychiatric history. No black-box warnings apply. Tools like the FDA label checker confirm compatibility.[1][2]
Sources
[1]: Wegovy FDA Label
[2]: Drugs.com Interaction Checker - Semaglutide
[3]: Lexicomp - Semaglutide Interactions
[4]: UpToDate - GLP-1 Agonists and Psychiatric Meds
[5]: Novo Nordisk Post-Marketing Safety Update
[6]: NEJM STEP 1 Trial